A pharmacist-led follow-up program for patients with coronary heart disease in North Norway--a qualitative study exploring patient experiences

Beate Hennie Garcia, Sissel Lisa Storli, Lars Småbrekke, Beate Hennie Garcia, Sissel Lisa Storli, Lars Småbrekke

Abstract

Background: Coronary heart disease (CHD) is one of the leading causes of death worldwide. Scientific literature shows that prevention of CHD is inadequate. The clinical pharmacist's role in patient-centred care has been shown favourable in a large amount of studies, also in relation to reduction of risk factors related to CHD. We developed and piloted a pharmacist-led follow-up program for patients with established CHD after hospital discharge from a hospital in North Norway. The aim of the present study was to explore how participants in the follow-up program experienced the program with regard to four main topics; medication knowledge, feeling of safety and comfort with medications, the functionality of the program and the clinical pharmacist's role in the interdisciplinary team.

Methods: We performed semi-structured thematic interviews with four patients included in the program. After verbatim transcribing, we analysed the interviews using "qualitative content analyses" by Graneheim and Lundman. Trial registration http://www.clinicaltrials.gov: NCT01131715.

Results: All participants appreciated the follow-up program because their medication knowledge had increased, participation had made them feel safe, they were reassured about the appropriateness of their medications, and they had become more involved in their own medication. The participants reported that the program was well structured and the clinical pharmacist was said to be an important caretaker in the health-care system. The importance of collaboration between pharmacists and physicians, both in hospital and primary care, was emphasized.

Conclusion: Our results indicate that the follow-up program was highly appreciated among the four participants included in this study. The results must be interpreted in the context of the health care system in Norway today. Here, few pharmacists are working in hospitals or in close relation to the general practitioners. In addition, physicians are short of time in order to supply appropriate medication information, both in hospital and primary care. Involving pharmacists in follow-up of patients with CHD seems to be highly appreciated among patients and may be a step towards improving patient care. The study is limited by the low number of participants.

References

    1. Mackay J, Mensah G. Atlas of Heart Disease and Stroke. Part III, Chapter 14 Deaths from Coronary Heart Disease; 2004. [ ] Accessed 2014-03-24.
    1. Kotseva K, Wood D. The challenge for preventive cardiology. Eur J Cardiovasc Prev Rehabil. 2009;16(Suppl 2):S19–S23.
    1. Kotseva K. Treatment of patients with coronary heart disease fails to meet standards of european guidelines: results of EUROASPIRE surveys. Rev Esp Cardiol. 2009;62(10):1095–1098. doi: 10.1016/S0300-8932(09)72377-2.
    1. WooD DA, Kotseva K, Connolly S, Jennings C, Mead A, Jones J, Holden A, De Bacquer D, Collier T, De Backer G, Faergeman O. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet. 2008;371(9629):1999–2012. doi: 10.1016/S0140-6736(08)60868-5.
    1. Till LT, Voris JC, Horst JB. Assessment of clinical pharmacist management of lipid-lowering therapy in a primary care setting. J Manag Care Pharm. 2003;9(3):269–273.
    1. Hunt JS, Siemienczuk J, Pape G, Rozenfeld Y, MacKay J, LeBlanc BH, Touchette D. A randomized controlled trial of team-based care: impact of physician-pharmacist collaboration on uncontrolled hypertension. J Gen Intern Med. 2008;23(12):1966–1972. doi: 10.1007/s11606-008-0791-x.
    1. Bailey TC, Noirot LA, Blickensderfer A, Rachmiel E, Schaiff R, Kessels A, Braverman A, Goldberg A, Waterman B, Dunagan WC. An intervention to improve secondary prevention of coronary heart disease. Arch Intern Med. 2007;167(6):586–590. doi: 10.1001/archinte.167.6.586.
    1. Axtell SS, Ludwig E, Lope-Candales P. Intervention to improve adherence to ACC/AHA recommended adjunctive medications for the management of patients with an acute myocardial infarction. Clin Cardiol. 2001;24(2):114–118. doi: 10.1002/clc.4960240204.
    1. Chapman NR, Fotis MA, Yarnold PR, Gheorghiade M. Pharmacist interventions to improve the management of coronary artery disease. Am J Health Syst Pharm. 2004;61(24):2672–2678.
    1. Horning KK, Hoehns JD, Doucette WR. Adherence to clinical practice guidelines for 7 chronic conditions in long-term-care patients who received pharmacist disease management services versus traditional drug regimen review. J Manag Care Pharm. 2007;13(1):28–36.
    1. The Framingham Risk Score. [ ] - Accessed 2014-03-24.
    1. Taveira TH, Wu WC, Martin OJ, Schleinitz MD, Friedmann P, Sharma SC. Pharmacist-led cardiac risk reduction model. Prev Cardiol. 2006;9(4):202–208. doi: 10.1111/j.1520-037X.2006.05339.x.
    1. Reilly V, Cavanagh M. The clinical and economic impact of a secondary heart disease prevention clinic jointly implemented by a practice nurse and pharmacist. Pharm World Sci. 2003;25(6):294–298.
    1. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296(21):2563–2571. doi: 10.1001/jama.296.21.joc60162.
    1. Lalonde L, Hudon E, Goudreau J, Belanger D, Villeneuve J, Perreault S, Blais L, Lamarre D. Physician-pharmacist collaborative care in dyslipidemia management: the perception of clinicians and patients. Res Social Adm Pharm. 2011;7(3):233–245. doi: 10.1016/j.sapharm.2010.05.003.
    1. Lambert-Kerzner A, Havranek EP, Plomondon ME, Albright K, Moore A, Gryniewicz K, Magid D, Ho PM. Patients' perspectives of a multifaceted intervention with a focus on technology: a qualitative analysis. Circ Cardiovasc Qual Outcomes. 2010;3(6):668–674. doi: 10.1161/CIRCOUTCOMES.110.949800.
    1. Wheeler A, Crump K, Lee M, Li L, Patel A, Yang R, Zhao J, Jensen M. Collaborative prescribing: A qualitative exploration of a role for pharmacists in mental health. Res Social Adm Pharm. 2012;8(3):179–92. doi: 10.1016/j.sapharm.2011.04.003.
    1. Tsiantou V, Pantzou P, Pavi E, Koulierakis G, Kyriopoulos J. Factors affecting adherence to antihypertensive medication in Greece: results from a qualitative study. Patient Prefer Adherence. 2010;4:335–343.
    1. Bereznicki B, Peterson G, Jackson S, Haydn WE, DeBoos I, Hintz P. Perceived feasibility of a community pharmacy-based asthma intervention: a qualitative follow-up study. J Clin Pharm Ther. 2011;36(3):348–355. doi: 10.1111/j.1365-2710.2010.01187.x.
    1. Guerreiro M, Cantrill J, Martins P. Acceptability of community pharmaceutical care in Portugal: a qualitative study. J Health Serv Res Pol. 2010;15(4):215–222. doi: 10.1258/jhsrp.2010.009121.
    1. Mahmoud HF. Eng: Pharmaceutical follow-up of patients with coronary heart disease: a qualitative study of patient experiences. University of Tromsoe, Department of Pharmacy; 2010. Farmasøytisk oppfølging av pasienter med hjertesykdom: en kvalitativ studie av pasientenes erfaringer. (Masters thesis). [ ] Accessed 2014-03-24.
    1. Graneheim UH, Lundman B. Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today. 2004;24(2):105–112. doi: 10.1016/j.nedt.2003.10.001.
    1. The World Medical Association. Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. 2008. Report. [ ] Accessed 2014-03-24.
    1. Horne R, Weinman J, Barber N, Elliot R. Concordance, adherence and compliance in medicine taking: report for the National Co-ordinating Centre for NHS Sercive Delivery and Organisation R&D (NCCSDO) 2005. Report. [ ]
    1. Aronson JK. Compliance, concordance, adherence. Br J Clin Pharmacol. 2007;63(4):383–384. doi: 10.1111/j.1365-2125.2007.02893.x.
    1. Hanlon JT, Weinberger M, Samsa GP, Schmader KE, Uttech KM, Lewis IK, Cowper PA, Landsman PB, Cohen HJ, Feussner JR. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med. 1996;100(4):428–437. doi: 10.1016/S0002-9343(97)89519-8.
    1. Strand LM, Cipolle RJ, Morley PC, Frakes MJ. The impact of pharmaceutical care practice on the practitioner and the patient in the ambulatory practice setting: twenty-five years of experience. Curr Pharm Des. 2004;10(31):3987–4001. doi: 10.2174/1381612043382576.
    1. Viktil KK, Blix HS, Moger TA, Reikvam A. Interview of patients by pharmacists contributes significantly to the identification of drug-related problems (DRPs) Pharmacoepidemiol Drug Saf. 2006;15(9):667–674. doi: 10.1002/pds.1238.
    1. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533–543.
    1. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, Magid DJ. Effect of Medication Nonadherence on Hospitalization and Mortality Among Patients With Diabetes Mellitus. Arch Intern Med. 2006;166(17):1836–1841. doi: 10.1001/archinte.166.17.1836.
    1. Barnett MJ, Frank J, Wehring H, Newland B, VonMuenster S, Kumbera P, Halterman T, Perry PJ. Analysis of pharmacist-provided medication therapy management (MTM) services in community pharmacies over 7 years. J Manag Care Pharm. 2009;15(1):18–31.
    1. LOV 2000-06-02 nr 39: Lov om apotek (apotekloven) [Eng: Norwegian Law concerning Pharmacies of June 2, 2000] Statute; [ ] Accessed 2014-03-24.
    1. Dahlberg K, Dahlberg H, Nystrøm M. An open lifeworld approach. 2. Lund: Studentlitteratur; 2008. pp. 95–121. (Reflective Lifeworld Research).
    1. Horsburgh D. Evaluation of qualitative research. J Clin Nurs. 2003;12(2):307–312. doi: 10.1046/j.1365-2702.2003.00683.x.
    1. Cutcliffe JR, McKenna HP. Establishing the credibility of qualitative research findings: the plot thickens. J Adv Nurs. 1999;30(2):374–380. doi: 10.1046/j.1365-2648.1999.01090.x.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe